Rahul Khara sold $471k of IRON
Chief Legal Officer at Disc Medicine, Inc.. 7,500 shares at an average of $62.75, traded Jan 2, 2025, filed Jan 6, 2025.
Score components
- +15RoleOfficer
- +17Trade size$471k at market
- +10Share of holdings soldSold 35% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-002373, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 2, 2025 | MOption exercise Common Stock10b5-1 | +7,500 | $14.69 | $110k | 21,535 | Jan 6, 2025 |
| Jan 2, 2025 | SOpen-market sale Common Stock10b5-1 | -4,000 | $61.96 | $248k | 17,535 | Jan 6, 2025 |
| Jan 2, 2025 | SOpen-market sale Common Stock10b5-1 | -1,400 | $62.95 | $88k | 16,135 | Jan 6, 2025 |
| Jan 2, 2025 | SOpen-market sale Common Stock10b5-1 | -2,100 | $64.13 | $135k | 14,035 | Jan 6, 2025 |
| Jan 2, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,500 | $0.00 | $0 | 72,304 | Jan 6, 2025 |
Related signals
Other insiders at Disc Medicine, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | IRONsell Disc Medicine, Inc. | Kevin Bitterman director | $1.9M 27,136 shares | -100% | |
| 6Weak | Disc Medicine, Inc. | Kevin Bitterman director | $135k 1,689 shares | -1% | |
| 25Weak | Disc Medicine, Inc. | Kevin Bitterman director | $4.4M 54,496 shares | -16% | |
| 6Weak | Disc Medicine, Inc. | Kevin Bitterman director | $140k 2,287 shares | -0% | |
| 20Weak | Disc Medicine, Inc. | Kevin Bitterman director | $2.0M 32,174 shares | -5% | |
| 0Weak | Disc Medicine, Inc. | Kevin Bitterman director | $24k 395 shares | -0% | |
| 13Weak | Disc Medicine, Inc. | Kevin Bitterman director | $518k 8,492 shares | -1% | |
| 40Moderate | IRONsell Disc Medicine, Inc. | Kevin Bitterman director | $2.6M 42,870 shares | -6% | |
| 21Weak | IRONsell Disc Medicine, Inc. | Kevin Bitterman director | $41k 664 shares | -0% | |
| 20Weak | Disc Medicine, Inc. | Jean M. Franchi Chief Financial Officer | $105k 2,000 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.